Oslo, Norway, 5 February 2026. Reference is made to the stock exchangeannouncement by EXACT Therapeutics AS (the “Company”, Euronext Growth ticker:EXTX), a clinical-stage precision medicine company, earlier today on 5February2026, confirming that GE Medical Holdings AB (“GEMH”) will exercise of all ofits 26,973,169 warrants.

The Company is pleased to announce that the following major shareholders andprimary insiders today have confirmed that they will exercise all of theirwarrants, as follows:

o Investinor Direkte AS, a close associate of board member Ann-ToveKongsnes:4,875,920 warrantso Helene Sundt AS, a close associate of board member Leiv Askvig:2,050,577warrantso Sundt AS, a close associate of board member Leiv Askvig: 420,396warrantso Basen Kapital AS, a close associate of board member Leiv Askvig: 87,107warrantso Anders Wold, chair of the Company: 69,685 warrantso Canica AS: 3,273,334 warrants

The exercise of the above-mentioned warrants, combined with the warrantsexercised by GEMH, accounts for 75% of the total warrants issued inconjunctionwith the private placement completed in December 2024, corresponding to grossproceeds of NOK 46 million.

The remaining warrants holders may exercise their warrants within 21 February2026. Updates on the warrant exercise will follow in due course.

As soon as the Company has confirmation from the remaining warrants holders onwhether they will exercise their warrants, the Company will call for anextraordinary general meeting to ensure that the relevant number of new sharesare issued.

Further, please find attached an updated corporate presentation which may alsobe found in the Investors section of the Company’s webpage.

Please see the attached PDMR notification in accordance with Regulation EU596/2014 (MAR) article 19 for further details.

About EXACT Therapeutics:EXACT Therapeutics is a clinical-stage precision medicine company utilizingthepower of ultrasound to activate the proprietary drug PS101 and enhance theclinical benefit of oncology therapies. PS101 has a unique mode of action andmay be combined with a wide range of therapeutic agents within oncology andacross a multitude of other indications, including brain diseases. EXACTTherapeutics’ shares are traded on Euronext Growth Oslo (EXTX). Furtherinformation may be found here:www.exact-tx.com

For further information, please contact:Per WaldayCEO EXACT TherapeuticsEmail: per.walday@exact-tx.com

https://newsweb.oslobors.no/message/664908